Amgen Inc (AMGN) - Total Liabilities
Based on the latest financial reports, Amgen Inc (AMGN) has total liabilities worth $81.93 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Amgen Inc (AMGN) long-term investment share to see how much of total assets are deployed in long-term investments.
Amgen Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Amgen Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AMGN total asset value.
Amgen Inc Competitors by Total Liabilities
The table below lists competitors of Amgen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marvell Technology Group Ltd
NASDAQ:MRVL
|
USA | $9.02 Billion |
|
Toronto Dominion Bank
TO:TD
|
Canada | CA$1.98 Trillion |
|
HERMES INTL UNSP.ADR 1/10
F:HMIA
|
Germany | €5.77 Billion |
|
Nestle S.A.
SW:NESN
|
Switzerland | CHF98.88 Billion |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
China | CN¥724.93 Billion |
|
Shopify Inc
NYSE:SHOP
|
USA | $2.53 Billion |
|
Verizon Communications Inc
SA:VERZ34
|
Brazil | R$304.99 Billion |
|
Mitsubishi UFJ Financial Group Inc ADR
NYSE:MUFG
|
USA | $407.03 Trillion |
Liability Composition Analysis (1985–2025)
This chart breaks down Amgen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AMGN net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amgen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amgen Inc (1985–2025)
The table below shows the annual total liabilities of Amgen Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $81.93 Billion | -4.69% |
| 2024-12-31 | $85.96 Billion | -5.46% |
| 2023-12-31 | $90.92 Billion | +47.94% |
| 2022-12-31 | $61.46 Billion | +12.84% |
| 2021-12-31 | $54.47 Billion | +1.73% |
| 2020-12-31 | $53.54 Billion | +7.01% |
| 2019-12-31 | $50.03 Billion | -7.20% |
| 2018-12-31 | $53.92 Billion | -1.46% |
| 2017-12-31 | $54.71 Billion | +14.58% |
| 2016-12-31 | $47.75 Billion | +10.11% |
| 2015-12-31 | $43.37 Billion | +0.31% |
| 2014-12-31 | $43.23 Billion | -1.81% |
| 2013-12-31 | $44.03 Billion | +24.95% |
| 2012-12-31 | $35.24 Billion | +18.08% |
| 2011-12-31 | $29.84 Billion | +52.71% |
| 2010-12-31 | $19.54 Billion | +15.21% |
| 2009-12-31 | $16.96 Billion | +5.64% |
| 2008-12-31 | $16.06 Billion | -4.25% |
| 2007-12-31 | $16.77 Billion | +13.13% |
| 2006-12-31 | $14.82 Billion | +67.58% |
| 2005-12-31 | $8.85 Billion | -7.04% |
| 2004-12-31 | $9.52 Billion | +41.52% |
| 2003-12-31 | $6.72 Billion | +8.98% |
| 2002-12-31 | $6.17 Billion | +403.30% |
| 2001-12-31 | $1.23 Billion | +12.98% |
| 2000-12-31 | $1.09 Billion | +2.94% |
| 1999-12-31 | $1.05 Billion | -5.04% |
| 1998-12-31 | $1.11 Billion | +14.33% |
| 1997-12-31 | $970.90 Million | +12.99% |
| 1996-12-31 | $859.30 Million | +12.92% |
| 1995-12-31 | $761.00 Million | +5.72% |
| 1994-12-31 | $719.80 Million | +21.28% |
| 1993-12-31 | $593.50 Million | +34.70% |
| 1992-12-31 | $440.60 Million | +31.76% |
| 1991-12-31 | $334.40 Million | +188.28% |
| 1990-12-31 | $116.00 Million | -3.33% |
| 1989-12-31 | $120.00 Million | +165.49% |
| 1988-12-31 | $45.20 Million | +54.27% |
| 1987-12-31 | $29.30 Million | +128.91% |
| 1986-12-31 | $12.80 Million | -2.29% |
| 1985-12-31 | $13.10 Million | -- |
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more